不同新型降糖药在2型糖尿病患者中的心血管改善作用进展  

Progression of Cardiovascular Improvement of Different Novel Antidiabetic Drugs in Patients with Type 2 Diabetes

作　　者：王茹[1] 姚朱华[1] WANG Ru;YAO Zhuhua(Department of Cardiology,Tianjin People's Hospital,Tianjin,300121,China)

机构地区：[1]天津市人民医院,天津300121

出　　处：《现代诊断与治疗》2024年第11期1619-1622,共4页Modern Diagnosis and Treatment

摘　　要：2型糖尿病是导致心血管疾病死亡的重要原因之一,合理控制血糖,可降低心血管疾病的发生风险,改善心血管疾病患者的预后结局。传统降糖药仅能降低血糖,对大血管合并症影响较小,而新型降糖药在2型糖尿病患者降糖预后方面有着诸多优势,也取得了较好的临床效果。新型降糖药包括肠促胰素类药物、二肽基肽酶-4抑制剂、钠-葡萄糖协同转运蛋白2抑制剂、葡萄糖激酶激动剂、胰岛淀粉样物多肽类似物等。本文总结2型糖尿病合并心血管疾病的发病现状,探讨不同新型降糖药对2型糖尿病患者心血管保护作用,展望不同新型降糖药物未来应用方向。Type 2 diabetes is an important cause of death from cardiovascular disease.Reasonable glucose control can reduce the risk of cardiovascular disease and improve the prognostic outcomes of cardiovascular disease patients.Traditional hypoglycemic drugs only reduce blood glucose and have less impact on macrovascular complications,while new hypoglycemic drugs have many advantages in the hypoglycemic prognosis of type 2 diabetes patients and have also achieved good clinical results.These drugs include incretin drugs,dipeptidyl peptidase-4 inhibitors,sodium-glucose cotransporter 2 inhibitors,glucokinase agonists,islet amyloid peptide analogs,etc.This paper summarizes the current situation of type 2 diabetes with cardiovascular disease,discusses the cardiovascular protection of different new hypoglycemic drugs in type 2 diabetes patients,and looks forward to the future applicationdirection of different new hypoglycemic drugs.

关 键 词：心血管保护作用 心血管疾病 新型降糖药物 肠促胰素类药物 二肽基肽酶-4抑制剂 

分 类 号：R587.1[医药卫生—内分泌]